US 11529395
Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
granted A61KA61K38/36A61K38/37
Quick answer
US patent 11529395 (Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF) held by Takeda Pharmaceutical Company Limited expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K38/36, A61K38/37, A61P, A61P7/04